MDS Foundation Xth Eurasian Hematology-Oncology Congress 2019

Overview

85 videos + 5 pdfs, size: 19.3 GB

List of Topics:

Cancer Immunotherapy in Lung Cancer Course 1.mp4
Cancer Immunotherapy in Lung Cancer Course 2.mp4
Cancer Immunotherapy in Lung Cancer Course 3.mp4
EHOC 2019 NURSING PROGRAM V3 23.09.pdf
EHOC 2019 PEDIATRIC HEMATOLOGY DRAFT PROGRAM v5 24.09.pdf
EHOC-2019-HEMATOLOGY-PROGRAM-v10-25-09.pdf
EHOC-2019-ONCOLOGY-PROGRAM-V8-4-10.pdf
SESSION I – PRECISION AND MOLECULAR ONCOLOGY – The Bio-Informatics of Precision Cancer Medicine.mp4
SESSION I – PRECISION AND MOLECULAR ONCOLOGY – Touching Cell Cyle and DNA Repairing- CDK Inhibitors and PARP Inhibitors in Solid Tumors.mp4
SESSION I – PRECISION HEMATOLOGY IN MYELOID MALIGNANCIES – Negative Myeloproliferative Neoplasms.mp4
SESSION I – PRECISION HEMATOLOGY IN MYELOID MALIGNANCIES – Precision Hematology in CML.mp4
SESSION I – PRECISION HEMATOLOGY IN MYELOID MALIGNANCIES – Precision Hematology in MDS.mp4
SESSION II – HIGHLIGHTS FROM SOHO – SOHO Updates on ALL.mp4
SESSION II – HIGHLIGHTS FROM SOHO – SOHO Updates on AML.mp4
SESSION II – HIGHLIGHTS FROM SOHO – SOHO Updates on CML.mp4
SESSION II – HIGHLIGHTS FROM SOHO – SOHO Updates on MDS.mp4
SESSION II – IMMUNE ONCOLOGY (BASIC) – Cancer Vaccine – A New Therapeutic Way.mp4
SESSION II – IMMUNE ONCOLOGY (BASIC) – Glycan-specific natural antibodies – from diagnosis to threrapy in cancer.mp4
SESSION II – IMMUNE ONCOLOGY (BASIC) – Natural Killer Cells in Oncology.mp4
SESSION II – IMMUNE ONCOLOGY (BASIC) – Precision Immune Medicine in cancer.mp4
SESSION III – EHOG – RUSSIAN ONCOHEMATOLOGY SOCIETY JOINT SESSION – BMT Efficacy with Multiple Myelomas. Practical Issues Based on Moscow National Hematological Center Experience.mp4
SESSION III – EHOG – RUSSIAN ONCOHEMATOLOGY SOCIETY JOINT SESSION – Bone Marrow Allogeneic Transplantation in Oncohematology (Saint-Petersburg Hematology Center Experience).mp4
SESSION III – EHOG – RUSSIAN ONCOHEMATOLOGY SOCIETY JOINT SESSION – The Use of BMT with Malignant Lymphomas. Practical Issues based on St-Petersburg Hematological Center Experience.mp4
SESSION III – EHOG – RUSSIAN ONCOHEMATOLOGY SOCIETY JOINT SESSION – Unrelated Donorship in Russia. Donors’ Register (Kirov Hematological Institute).mp4
SESSION III – IMMUNE ONCOLOGY (CLINIC) – Allogenic Transplantation as a Model for Immune Therapy in Oncology.mp4
SESSION IV – ACUTE LYMPHOID LEUKEMIAS – Current Therapy of Ph Positive ALL.mp4
SESSION IV – ACUTE LYMPHOID LEUKEMIAS – Should ALL Treatment Be Driven by MRD Detection.mp4
SESSION IV – ACUTE LYMPHOID LEUKEMIAS – Should the Ph-like ALL Therapy be Different From the Other B ALL No.mp4
SESSION IV – ACUTE LYMPHOID LEUKEMIAS – Should the Ph-like ALL Therapy be Different From the Other B ALL Yes.mp4
SESSION IV – HEAD AND NECK CANCER – HPV-Associated Head Neck Cancer- New Stagings and New Treatments 1.mp4
SESSION IV – HEAD AND NECK CANCER – HPV-Associated Head Neck Cancer- New Stagings and New Treatments 2.mp4
SESSION IV – HEAD AND NECK CANCER – p16-Negative Advanced Head and Neck Cancer.mp4
SESSION IV – HEAD AND NECK CANCER – Tumor-Related Factors Warranting Adjuvant Postoperative Therapy in Head and Neck Cancer 1.mp4
SESSION IV – HEAD AND NECK CANCER – Tumor-Related Factors Warranting Adjuvant Postoperative Therapy in Head and Neck Cancer 2.mp4
SESSION IX – ACUTE MYELOID LEUKEMIA – Current Therapeutic Options in AML of Young Adults.mp4
SESSION IX – ADVANCED METASTATIC BREAST CANCER – Optimizing Therapy for ER-Positive Metastatic Breast Cancer.mp4
SESSION IX – ADVANCED METASTATIC BREAST CANCER – Overcoming Resistance in HER2+ Metastatic Breast Cancer 1.mp4
SESSION IX – ADVANCED METASTATIC BREAST CANCER – Overcoming Resistance in HER2+ Metastatic Breast Cancer 2.mp4
SESSION IX – ADVANCED METASTATIC BREAST CANCER – Shining Side of the Moon; PARP Inhibitors in Triple Negative Breast Cancer.mp4
SESSION V – NON-SMALL CELL LUNG CANCER – Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy 1.mp4
SESSION V – NON-SMALL CELL LUNG CANCER – Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy 2.mp4
SESSION V – NON-SMALL CELL LUNG CANCER – Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer 1.mp4
SESSION V – NON-SMALL CELL LUNG CANCER – Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer 2.mp4
SESSION V – PNH and COAGULATION PROBLEMS – Approaching Consensus in ITP.mp4
SESSION V – PNH and COAGULATION PROBLEMS – Disgnosis and Treatment in PNH.mp4
SESSION V – PNH and COAGULATION PROBLEMS – Eosinophilia and Mastocytosis- Another Shade of MPN.mp4
SESSION V – PNH and COAGULATION PROBLEMS – Hemostasis Changes in PNH.mp4
SESSION VI – BEST SELECTED ORAL PRESENTATIONS – Best Abstract Presentation (Atilla Yalcin Prize) – Transplant.mp4
SESSION VI – BEST SELECTED ORAL PRESENTATIONS – Best Abstract Presentation (Ekrem Muftuoglu Prize) – Oncology Evaluation of Secondary Hypogammaglobulinemia in Patients.mp4
SESSION VI – BEST SELECTED ORAL PRESENTATIONS – Best Abstract Presentation (Eliezer Rachmilewitz Prize) – Adult Hematology.mp4
SESSION VI – BEST SELECTED ORAL PRESENTATIONS – Best Abstract Presentation (Francesco Lo Coco Prize) – Adult Hematology A Retrospective Analysis of Peripheral T-Cell Lymphoma Patients Single.mp4
SESSION VI – BEST SELECTED ORAL PRESENTATIONS – Best Abstract Presentation (Giuseppe Saglio Prize) – Presidential.mp4
SESSION VI – EARLY BREAST CANCER – Adjuvant Therapy in ER+ HER2- Breast Cancer- Chemotherapy or Not.mp4
SESSION VI – EARLY BREAST CANCER – Challenging Adjuvant Therapy in HER2+ Breast Cancer- Escalating or De-escalating.mp4
SESSION VI – EARLY BREAST CANCER – Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings 1.mp4
SESSION VI – EARLY BREAST CANCER – Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings 2.mp4
SESSION VII – COLORECTAL CANCER – Is Tumor Sideness, Biomarkers or Molecular Subtype Classification More Predictive for the Treatment of Unresectable Metastatic Colon Cancer.mp4
SESSION VII – COLORECTAL CANCER – Systemic Therapy for Potentially Resectable Metastatic Rectal Cancer.mp4
SESSION VIII – CHRONIC MYELOID LEUKEMIA – Generic TKI’s in CML Therapy.mp4
SESSION VIII – NON – COLORECTAL TUMORS – Has Sorafenib Still Been the Real Winner Against New Generation TKIs and Immune Checkpoint Inhibitors in HCC.mp4
SESSION VIII – NON – COLORECTAL TUMORS – Metastatic Well-Differentiated Gastrointestinal Neuroendocrine (Carcinoid) Tumors- Systematic Therapy Options.mp4
SESSION VIII – NON – COLORECTAL TUMORS – New (neo-)adjuvant Standards of Care in Gastro-esophageal Cancer.mp4
SESSION VIII – NON – COLORECTAL TUMORS – Treatment for recurrent disease following Adjuvant treatment of GIST.mp4
SESSION VIII – NON – COLORECTAL TUMORS – What is Changed in the Treatment of Biliary Tract Cancer.mp4
SESSION X – URO-ONCOLOGY – Approach to Stage I Testicular Cancer- Who Needs Treatment and Which One.mp4
SESSION X – URO-ONCOLOGY – Perioperative Systemic Therapy for Localized Renal Cell Carcinoma – To Treat or Not to Treat.mp4
SESSION X – URO-ONCOLOGY – Perioperative Systemic Therapy for Localized Renal Cell Carcinoma- To Treat or Not to Treat.mp4
SESSION X – URO-ONCOLOGY – Treatment of Cisplatin-Ineligible Metastatic Bladder Cancer.mp4
SESSION X – URO-ONCOLOGY – What is the Role and Best Sequencing of the New Generation Hormonal Agents in the Treatment of Both Hormone Sensitive and Resistant Metastatic Prostate Cancer 1.mp4
SESSION X – URO-ONCOLOGY – What is the Role and Best Sequencing of the New Generation Hormonal Agents in the Treatment of Both Hormone Sensitive and Resistant Metastatic Prostate Cancer 2.mp4
SESSION XI – SKIN CANCER – Markers for immune checkpoint inhibitor resistance.mp4
SESSION XI – SKIN CANCER – The evolution of metastatic melanoma treatment. What’s next.mp4
SESSION XI – SKIN CANCER – Update on neoadjuvant adjuvant treatment of melanoma 1.mp4
SESSION XI – SKIN CANCER – Update on neoadjuvant adjuvant treatment of melanoma 2.mp4
SESSION XII – SARCOMA – Can We Ever Have a Specific Treatment for Every 50 Subtypes of Soft Tissue Sarcoma.mp4
SESSION XII – SARCOMA – Molecular and morphological diagnosis in bone and soft tissue tumors.mp4
SESSION XII – SARCOMA – Small round cell tumors.mp4
SESSION XIII- CHRONIC LYMPHOCYTIC LEUKEMIAS AND INDOLENT LYMPHOMAS – Molecular Markers in CLL.mp4
SESSION XIII- CHRONIC LYMPHOCYTIC LEUKEMIAS AND INDOLENT LYMPHOMAS – Risk Stratification and Treatment of CLL.mp4
SESSION XIV – EHOG – ASFA JOINT SYMPOSIUM – Update on collections for HPC and CAR-T.mp4
SESSION XIV – EHOG – ASFA JOINT SYMPOSIUM – Update on Extracorporeal Photopheresis (ECP).mp4
SESSION XIV – EHOG – ASFA JOINT SYMPOSIUM – Update on Therapeutic Apheresis Indications.mp4
SESSION XV – MULTIPLE MYELOMA – How I Treat Multiple Myeloma.mp4
SESSION XV – MULTIPLE MYELOMA – Impact of Continuous First-Line Therapy in the Treatment of the First Relapse in Multiple Myeloma.mp4
SESSION XV – MULTIPLE MYELOMA – Importance of Minimal Disease Detection in Multiple Myeloma.mp4
SESSION XVI – STEM CELL TRANSPLANT AND CELLULAR IMMUNO THERAPY – Are Maintenance Postransplant Therapies Needed.mp4
SESSION XVI – STEM CELL TRANSPLANT AND CELLULAR IMMUNO THERAPY – Oral Manifestations of Oral Chronic Graft-Versus-Host Disease.mp4
SESSION XVI – STEM CELL TRANSPLANT AND CELLULAR IMMUNO THERAPY – The Secretome of Malignant Effusions- Clues to Targets of Therapy.mp4
SESSION XVI – STEM CELL TRANSPLANT AND CELLULAR IMMUNO THERAPY – Will Car T-Cell Therapy Replace Hematopoietic Stem Cells Transplant.mp4
Xth Eurasian Hematology-Oncology Congress 2019 Course Syllabus.pdf